Article thumbnail

Mining a Cathepsin Inhibitor Library for New Antiparasitic Drug Leads

By Kenny K. H. Ang, Joseline Ratnam, Jiri Gut, Jennifer Legac, Elizabeth Hansell, Zachary B. Mackey, Katarzyna M. Skrzypczynska, Anjan Debnath, Juan C. Engel, Philip J. Rosenthal, James H. McKerrow, Michelle R. Arkin and Adam R. Renslo


The targeting of parasite cysteine proteases with small molecules is emerging as a possible approach to treat tropical parasitic diseases such as sleeping sickness, Chagas' disease, and malaria. The homology of parasite cysteine proteases to the human cathepsins suggests that inhibitors originally developed for the latter may be a source of promising lead compounds for the former. We describe here the screening of a unique ∼2,100-member cathepsin inhibitor library against five parasite cysteine proteases thought to be relevant in tropical parasitic diseases. Compounds active against parasite enzymes were subsequently screened against cultured Plasmodium falciparum, Trypanosoma brucei brucei and/or Trypanosoma cruzi parasites and evaluated for cytotoxicity to mammalian cells. The end products of this effort include the identification of sub-micromolar cell-active leads as well as the elucidation of structure-activity trends that can guide further optimization efforts

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A cysteine protease inhibitor cures Chagas’ disease in an immunodeficient-mouse model of infection.
  2. (1988). A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum.
  3. (2008). A parasite cysteine protease is key to host protein degradation and iron acquisition.
  4. (2001). Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense.
  5. (2003). Antimalarial drug discovery: old and new approaches.
  6. (2009). Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins.
  7. (2000). Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum.
  8. (1998). Chemotherapy of malaria.
  9. (2010). Comparison of the antiplasmodial and falcipain-2 inhibitory activity of beta-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids.
  10. (2009). Covalent Modifiers: An Orthogonal Approach to Drug Design.
  11. (1998). Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
  12. (1999). Cysteine protease inhibitors as chemotherapy for parasitic infections.
  13. (1998). Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection.
  14. (2004). Cysteine proteases of malaria parasites.
  15. (2002). Cysteine proteases of parasitic organisms.
  16. (2005). Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
  17. (2008). Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.
  18. (2006). Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei.
  19. (2006). Drug discovery and development for neglected parasitic diseases.
  20. (2008). Evidence of artemisinin-resistant malaria in western Cambodia.
  21. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
  22. (2001). Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3.
  23. (2010). Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series.
  24. (2004). Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.
  25. (2006). Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum.
  26. (2010). Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.
  27. (2010). Imagebased high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas’ disease.
  28. (2006). Keto1,3,4-oxadiazoles as cathepsin K inhibitors.
  29. (2006). Medicines for Malaria Venture: sustaining antimalarial drug development.
  30. MEROPS: the peptidase database.
  31. (2003). Nonleadlikeness and leadlikeness in biochemical screening.
  32. (2002). Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors.
  33. (1992). Peptidyl fluoromethyl ketones as inhibitors of cathepsin B. Implication for treatment of rheumatoid arthritis.
  34. (2006). Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.
  35. (1993). Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi.
  36. (2006). Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance.
  37. (1995). Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
  38. (2003). Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones.
  39. (2003). Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-Trisubstituted dihydroisoquinolines and isoquinolines.
  40. (2009). Structure-guided development of selective TbcatB inhibitors.
  41. (2006). Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery.
  42. (2004). Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi.
  43. (2007). Target assessment for antiparasitic drug discovery.
  44. (1995). The crystal structure of cruzain: a therapeutic target for Chagas’ disease.
  45. (2008). The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
  46. (2006). Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis).
  47. (1999). Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. Exp Parasitol 91:
  48. (1995). Vinyl sulfones as mechanism-based cysteine protease inhibitors.